Using Common Sense Reasoning to Enable the Semantic Web Sakda Chaiworawitkul, Alex Faaborg.
TRIPS and Public Health: Thailand’s Compulsory Licenses over Patented Drugs for Chronic Diseases...
-
Upload
gervais-edwards -
Category
Documents
-
view
215 -
download
2
Transcript of TRIPS and Public Health: Thailand’s Compulsory Licenses over Patented Drugs for Chronic Diseases...
![Page 1: TRIPS and Public Health: Thailand’s Compulsory Licenses over Patented Drugs for Chronic Diseases December 2, 2013 By Sakda Thanitcul.](https://reader036.fdocuments.net/reader036/viewer/2022070409/56649e8f5503460f94b93645/html5/thumbnails/1.jpg)
TRIPS and Public Health: Thailand’s
Compulsory Licenses over Patented Drugs for
Chronic DiseasesDecember 2, 2013
BySakda Thanitcul
![Page 2: TRIPS and Public Health: Thailand’s Compulsory Licenses over Patented Drugs for Chronic Diseases December 2, 2013 By Sakda Thanitcul.](https://reader036.fdocuments.net/reader036/viewer/2022070409/56649e8f5503460f94b93645/html5/thumbnails/2.jpg)
I. Introduction
TRIPS and flexibility (Article 31)Public health crisis
Access to essential medicines “Breakthrough (Blockbuster)” patented drugs
- Infectious diseases (HIV/AIDS, malaria, tuberculosis)
- Chronic diseases (Coronary heart disease, strokes, cancers, chronic lung disease, diabetes)
Compulsory licenses
![Page 3: TRIPS and Public Health: Thailand’s Compulsory Licenses over Patented Drugs for Chronic Diseases December 2, 2013 By Sakda Thanitcul.](https://reader036.fdocuments.net/reader036/viewer/2022070409/56649e8f5503460f94b93645/html5/thumbnails/3.jpg)
Why there is a problem?
Thailand’s authorization of compulsory licenses for
1. First line HIV/AIDS patented drug
(Efivarenz, Merke)
2. Second line HIV/AIDS patented drug
(Kaletra, Abbot)
3. Heart disease patented drug
(Plavix, Sanofi-Aventis)
![Page 4: TRIPS and Public Health: Thailand’s Compulsory Licenses over Patented Drugs for Chronic Diseases December 2, 2013 By Sakda Thanitcul.](https://reader036.fdocuments.net/reader036/viewer/2022070409/56649e8f5503460f94b93645/html5/thumbnails/4.jpg)
“Public non-commercial use” for
1. Civil servant medical benefit scheme
2. Social security scheme
3. Universal coverage scheme
![Page 5: TRIPS and Public Health: Thailand’s Compulsory Licenses over Patented Drugs for Chronic Diseases December 2, 2013 By Sakda Thanitcul.](https://reader036.fdocuments.net/reader036/viewer/2022070409/56649e8f5503460f94b93645/html5/thumbnails/5.jpg)
How compulsory licenses work in Thailand
1. Department of Disease Control issues Notification (Shorei) entrusting CL to Government Pharmaceutical Organization (GPO)
2. GPO imports generic drugs from India.
3. GPO sells imported generic drugs to state hospitals.
4. State hospitals dispense drugs to patients.
![Page 6: TRIPS and Public Health: Thailand’s Compulsory Licenses over Patented Drugs for Chronic Diseases December 2, 2013 By Sakda Thanitcul.](https://reader036.fdocuments.net/reader036/viewer/2022070409/56649e8f5503460f94b93645/html5/thumbnails/6.jpg)
WHO’s Report on “Double Burden”
35 million annual deaths due to non-communicable diseases in 2005.
41 million in 2015
80% of 35 million were in low-and-middle income country
In 2010, India will have the largest number of diabetics
![Page 7: TRIPS and Public Health: Thailand’s Compulsory Licenses over Patented Drugs for Chronic Diseases December 2, 2013 By Sakda Thanitcul.](https://reader036.fdocuments.net/reader036/viewer/2022070409/56649e8f5503460f94b93645/html5/thumbnails/7.jpg)
Double Burden vs. Trade Benefit
Double burden
- 2015, China will lose $ 131 billion
- 2015, India will lose $ 54 billion
Trade benefit
- 2015, China will gain $ 287 billion from free trade
The shrinking trade gain → to put at risk the whole intellectual property right system ??
Thailand
GSP (General System of Preference) vs. Public Health
MOC vs. MOPH?
![Page 8: TRIPS and Public Health: Thailand’s Compulsory Licenses over Patented Drugs for Chronic Diseases December 2, 2013 By Sakda Thanitcul.](https://reader036.fdocuments.net/reader036/viewer/2022070409/56649e8f5503460f94b93645/html5/thumbnails/8.jpg)
II. Policy Choices to Bring down Prices of Patented Drugs
1. Use competition laws
- Article 8 (abuse of IPRs; Morton Salt v. Suppiger)
- Article 40 (misuse of licensing agreeement; Microsoft II)
- Article 8 (United States v. Glaxo Group)
![Page 9: TRIPS and Public Health: Thailand’s Compulsory Licenses over Patented Drugs for Chronic Diseases December 2, 2013 By Sakda Thanitcul.](https://reader036.fdocuments.net/reader036/viewer/2022070409/56649e8f5503460f94b93645/html5/thumbnails/9.jpg)
- South AfricaHazel Tau et al. v. Glaxo Smith Kline and Boehringer
Ingelheim (settled in 2003)
- Can Thailand use a competition law? Inexperienced, weak institutional arrangement Complicated proceedings The change of facts
- CanadaParadise Pharmacy, Inc. v. Novartis Pharmaceuticals
Canada, Inc.(2004 Comp. Trib. 21)
![Page 10: TRIPS and Public Health: Thailand’s Compulsory Licenses over Patented Drugs for Chronic Diseases December 2, 2013 By Sakda Thanitcul.](https://reader036.fdocuments.net/reader036/viewer/2022070409/56649e8f5503460f94b93645/html5/thumbnails/10.jpg)
2. Use price control laws
Sugar, instant noodle, cooking oil or student uniform
Patented drug (ingredient, marketing and R&D)
OECD except the U.S. has price control mechanism on prescription drugs
Thailand removed the “drug patent committee” from its patent law
Canada uses “median price”
![Page 11: TRIPS and Public Health: Thailand’s Compulsory Licenses over Patented Drugs for Chronic Diseases December 2, 2013 By Sakda Thanitcul.](https://reader036.fdocuments.net/reader036/viewer/2022070409/56649e8f5503460f94b93645/html5/thumbnails/11.jpg)
2. Use TRIPS’ flexibility (Article 31) and the Doha Declaration
Efavirenze: 1,400 Baht ($40) down to 650 Baht ($18)
(500,000 patients)
Kaletra: down 80%
Plavix: accessibility 6-12 times higher
(300,000 patients) 2007 – 2011
84,000 patients could access 7,000 m. Baht (200 m.) was saved
![Page 12: TRIPS and Public Health: Thailand’s Compulsory Licenses over Patented Drugs for Chronic Diseases December 2, 2013 By Sakda Thanitcul.](https://reader036.fdocuments.net/reader036/viewer/2022070409/56649e8f5503460f94b93645/html5/thumbnails/12.jpg)
III. Are the Thai Government Measures TRIPS – Consistent?
Article 31 requirementsChapeau – the national law allows compulsory licensingSpecific (a) Considered on its merit
(b) “National emergency” or “circumstances of urgency” or “public non- commercial use”, the requirements to negotiate with the patent holder is waived
(c) Use as initially authorized(d) Such use shall be non-exclusive(e) Such use shall be non-assignable(f) Such use shall be predominantly for domestic market(g) Such use must be reviewed(h) The rights holder shall be paid adequate compensation(i) Legal validity must be reviewed(j) Compensation must be reviewed
![Page 13: TRIPS and Public Health: Thailand’s Compulsory Licenses over Patented Drugs for Chronic Diseases December 2, 2013 By Sakda Thanitcul.](https://reader036.fdocuments.net/reader036/viewer/2022070409/56649e8f5503460f94b93645/html5/thumbnails/13.jpg)
Note:
(1) Paragraph 6 of the Doha Declaration makes (f) and (h) more flexible
(2) Compulsory licensing under Article 31 is an important tool for negotiation (e.g. Brazil)
(3) Mozambique, Zimbabwe, Zambia, Malaysia, Indonesia, Guinee and Eritrea actually used compulsory licensing over HIV/AIDS patented drugs.
![Page 14: TRIPS and Public Health: Thailand’s Compulsory Licenses over Patented Drugs for Chronic Diseases December 2, 2013 By Sakda Thanitcul.](https://reader036.fdocuments.net/reader036/viewer/2022070409/56649e8f5503460f94b93645/html5/thumbnails/14.jpg)
Legal problems with “Plavix”
1. Does Thailand have to negotiate with Sanofi-Aventis? GPO is “for-profit” entity (Sanofi-Aventis) Paragraph 5(c) allows WTO members to identify “national
emergency” and “circumstances of extreme urgency” not “public non-commercial use” (Sanofi-Aventis)
Paragraph 4: Article 31 should be interpreted… to protect public health (Thai government)
2. Are chronic drugs included in the Doha Declaration? Paragraph 5(c) specifies HIV/AIDS, tuberculosis, malaria, and other
epidemics (Sanofi-Aventis) The U.S. Representative’s initial position limited solution to
HIV/AIDS, tuberculosis, and tuberculosis (Carlos Correa)
![Page 15: TRIPS and Public Health: Thailand’s Compulsory Licenses over Patented Drugs for Chronic Diseases December 2, 2013 By Sakda Thanitcul.](https://reader036.fdocuments.net/reader036/viewer/2022070409/56649e8f5503460f94b93645/html5/thumbnails/15.jpg)
IV. TRIPS and Future Public Health Crisis: Thailand Test China, India behave economically rational in the future
– shake the WTO system?
Test the ability of TRIPS and pharmaceutical industry to adapt to the “double burden” occurring in developing countries
Thailand, export benefit vs. public health
![Page 16: TRIPS and Public Health: Thailand’s Compulsory Licenses over Patented Drugs for Chronic Diseases December 2, 2013 By Sakda Thanitcul.](https://reader036.fdocuments.net/reader036/viewer/2022070409/56649e8f5503460f94b93645/html5/thumbnails/16.jpg)
Thank You Very Much for Your Kind Attention!!